Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Eligibility for Alirocumab or Evolocumab Treatment in 1090 Hypercholesterolemic Patients Referred to a Regional Cholesterol Treatment Center With LDL Cholesterol ≥70 Mg/Dl Despite Maximal Tolerated Cholesterol Lowering Therapy
  1. Home
  2. Publications
  3. Eligibility for Alirocumab or Evolocumab Treatment in 1090 Hypercholesterolemic Patients Referred to a Regional Cholesterol Treatment Center With LDL Cholesterol ≥70 Mg/Dl Despite Maximal Tolerated Cholesterol Lowering Therapy

Eligibility for Alirocumab or Evolocumab Treatment in 1090 Hypercholesterolemic Patients Referred to a Regional Cholesterol Treatment Center With LDL Cholesterol ≥70 Mg/Dl Despite Maximal Tolerated Cholesterol Lowering Therapy

Authors:
  • NGNaila Goldenberg
    Naila Goldenberg
  • KLKevin Lee
    Kevin Lee
  • MPMarloe Prince
    Marloe Prince
  • VJVybhav Jetty
    Vybhav Jetty
  • AKAshwin Kumar
    Ashwin Kumar
  • MGMichael Goldenberg
    Michael Goldenberg
  • PSParth Shah
    Parth Shah
  • PWPing Wang
    Ping Wang
  • CGCharles Glueck
    Charles Glueck

Publisher website
Google Scholar
  • 1 May 2017
    • journal article
    • Published by Elsevier in Journal of Clinical Lipidology
    • Vol. 11  (3) , 786
    • DOI:10.1016/j.jacl.2017.04.024
Abstract
No abstract available
Keywords
  • THERAPY
  • EVOLOCUMAB TREATMENT
  • ALIROCUMAB OR EVOLOCUMAB
  • ELIGIBILITY FOR ALIROCUMAB
  • HYPERCHOLESTEROLEMIC PATIENTS
  • PATIENTS REFERRED
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.